Theasaponin E₁ as an effective ingredient for anti-angiogenesis and anti-obesity effects
Jong-Deog Kim1, Narendra Chaudhary, Hyo-Jin Seo
1a Department of Biotechnology , Chonnam National University , Yeosu , Korea.
Abstract:
Theasaponin E₁ (TSE₁) has been suggested to have higher biological activity than other saponins present in tea seed. Saponins have recently been considered as a potential chemotherapeutic agent for treating cancer. We examined the anti-angiogenic and anti-obesity properties of TSE₁ contributing to anti-cancer efficacy. Treating with a 10 μg/mL concentration of TSE₁ completely inhibited tube formation in human umbilical vein endothelial cells (HUVECs). TSE₁ showed toxicity toward cancer cells and inhibited in vivo growth of the tumor. The vascular endothelial growth factor (VEGF) receptor complex was suppressed, leading to the inhibition of protein kinase B (Akt) expression and down-regulation of nuclear factor-kappa B (NF-kB) activation. The differentiating 3T3-L₁ cells treated with TSE₁ had decreased lipid droplet formation measured by Oil Red O staining. Reduced weight was measured in mice fed with a TSE₁ plus high-fat diet. The results taken together, and particularly the NF-kB inhibition, suggest that TSE₁ may have multi-target action for treating cancer as a novel chemotherapeutic agent.
Insights
Theasaponin E₁ (TSE₁) exhibits anti-cancer properties by inhibiting angiogenesis and tumor growth. This novel chemotherapeutic agent also demonstrates anti-obesity effects, suggesting multi-target therapeutic potential.
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- Saponins, including Theasaponin E₁ (TSE₁), are investigated for their potential as chemotherapeutic agents.
- TSE₁ is noted for potentially higher biological activity compared to other tea seed saponins.
Purpose of the Study:
- To evaluate the anti-angiogenic and anti-obesity effects of TSE₁.
- To assess the contribution of these properties to TSE₁'s anti-cancer efficacy.
Main Methods:
- Inhibition of human umbilical vein endothelial cell (HUVEC) tube formation.
- Assessment of cancer cell toxicity and in vivo tumor growth inhibition.
- Analysis of VEGF receptor complex, Akt, and NF-kB signaling pathways.
- Evaluation of lipid droplet formation in 3T3-L₁ cells and weight changes in mice on a high-fat diet.
Main Results:
- TSE₁ completely inhibited HUVEC tube formation at 10 μg/mL.
- TSE₁ demonstrated toxicity to cancer cells and suppressed tumor growth in vivo.
- Suppression of VEGF receptor complex, Akt, and NF-kB activation was observed.
- Reduced lipid droplet formation and decreased body weight were noted in TSE₁-treated models.
Conclusions:
- TSE₁ exhibits significant anti-angiogenic and anti-cancer activities.
- TSE₁ possesses anti-obesity properties, evidenced by reduced adipogenesis and weight gain.
- NF-kB inhibition by TSE₁ suggests a multi-target mechanism for novel cancer chemotherapeutic development.
